Recognizing the importance of collaboration, NAPT recently hosted its first Proton Therapy Research Symposium in partnership with key stakeholders, including the Proton Collaborative Group (PCG) and PTCOG-NA. This initiative underscores the commitment to advancing proton therapy through cooperative research efforts. One highly anticipated study is the randomized phase III trial led by Dr. Steven Frank at MD Anderson, comparing proton therapy versus IMRT for oropharyngeal head and neck cancer (OPC). The findings from this study will provide valuable insights into the role of proton therapy in reducing treatment toxicity while maintaining efficacy.

HCB News: The NAPT annual meeting brings together experts from across the industry. What unique opportunities does this year’s event offer for collaboration and learning?
JM: This year’s NAPT Annual Meeting promises to be an unparalleled opportunity for collaboration, education, and networking. Under the leadership of our Program Chair, Dr. Jeff Bradley, we’ve crafted an agenda that addresses both current challenges and future innovations in proton therapy.
One of the highlights is an exclusive tour of the Roberts Proton Therapy Center at Penn’s Abramson Cancer Center, a premier institution known for its excellence in clinical care, research, and patient support.

Other key sessions include: A keynote address by Dr. Arif Kamal, Chief Medical Officer of the American Cancer Society; The NAPT Excellence Awards Breakfast, recognizing leaders in the field; A PTCOG-NA session focused on defining the next generation of proton therapy research; Roundtable discussions tailored for administrators and their team fostering peer-to-peer learning; Sessions on optimizing workflow, navigating insurance and the appeals processes, the transformative role of AI in proton therapy, sustainable development and the latest advancements in clinical research.

HCB News: For hospitals or oncology practices considering adding proton therapy, what factors should they take into account before making that investment?
JM: Investing in proton therapy is a long-term commitment, and institutions must plan strategically to ensure sustainability and growth. A few key considerations include:

• Long-Term Vision: With more indications being treated with proton therapy, it’s crucial to plan for the future. This includes designing facilities that allow for technology upgrades and innovations.
• Clinical Expertise: Engaging experienced proton therapy professionals early in the process—both on the clinical and operational side—can significantly impact a center’s success. Learning from established programs can help avoid common pitfalls.

Proton Therapy Homepage